H P Sinn
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Karn T, Schmitt W, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, Higgs B, Jank P, Sinn H, Huober J, Becker C, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020; 31:1216-1222.
24.05.2020Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
24.05.2020Ann Oncol 2020; 31:1216-1222
Karn T, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J-U, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober Jens, Becker C, Loibl S
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]
Sinn H, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto H. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe und Frauenheilkunde 1994; 54:552-8.
01.10.1994[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]
01.10.1994Geburtshilfe und Frauenheilkunde 1994; 54:552-8
Sinn H P, Schmid H, Junkermann H, Huober Jens, Leppien G, Kaufmann M, Bastert G, Otto H F